Skip to main content

Table 2 Comparison of laboratory values and disease severity before and after Anti-IL-1 therapy

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

 Before treatmentAfter treatmentp
Attack frequency (per 3 months)3 (1–6)0 (0–1).00*
Patients-VAS (0–10 cm)10 (9–10)2 (0–3).00*
Physicians-VAS (0–10 cm)9 (8–10)1 (0–2).00*
ESR (mm/h)33 (9–85)29 (2–106).00*
CRP (mg/dl)16 (1–80)2 (1–12).00*
GFR (ml/min/m2)54 (13–180)42 (10–174).592
Durations of attacks (hours)48 (36–96)8 (0–24)0.0*
Proteinuria (mg/day)3200 (0.5–11.2)1850 (0.1–12.2)0.140
 GFR ≥ 60 ml/min/m22390 (1400–7200)890 (120–2.75)0.008*
 GFR < 60 ml/min/m24472 (1950–11.2)3960 (2050–12.2)0.345
  1. Values presented as median (minimum-maximum).VAS Visual Analogue Scale (0–10 cm), CRP C reactive protein, GFR glomerul filtration rate, ESR Erythrocyte Sedimentation Rate *: p < 0.05